CenExel Completes Metabolic Task Force Training Across Site Network

DRAPER, UTAH / ACCESS Newswire / February 4, 2026 / CenExel, a leading, wholly owned clinical research site network, recently completed its comprehensive Metabolic Task Force training, one of three Task Forces designed to advance a unified approach to patient-focused care.

The training is a direct response to the highly evolving pace of metabolic research, such as GLP-1s, and the growing need to navigate the complexities of emerging metabolic clinical trials. Ensuring clinical sites are equipped with the standardized tools fosters high quality outcomes while remaining compliant, keeping retention rates high and continued accelerated enrollment.

The training was led by Kimball Johnson, MD, Chief Medical Director, CenExel Metabolic in tandem with Registered Dietitians, Dr. Anna Parker, Beth DeLuca and Margot Witteveen, who held three separate two-hour sessions, training more than 200+ employees across the network.

“Metabolic clinical research is reshaping the practice of medicine,” said Dr. Johnson. “This training helped us understand how these therapies address the root cause of systemic inflammation and redefine what is possible across multiple indications. We have an opportunity to lead this seismic shift in chronic disease management for years to come.”

Some of the topic discussions during the sessions included:

• Read moreFossil launches its first smartwatch on the Qualcomm Snapdragon Wear 3100 platform

  How GLP-1s work, why it matters and navigating its common side effects

• Emotional impact of weight loss, body image and use of GLP-1s

• Overcoming societal stigmas around GLP-1 use

• Diabetes management

• Dietary guidelines and recommendations for nutrition and exercise

• Read moreConwy Care Home Multi-Professional Response wins Secure I.T. Environments Sponsored award at Betsi Cadwaladr University Health Board Achievement Awards

  Metabolism and nutrition counseling guardrails

“The discussion challenged my preexisting assumptions on GLP-1 medications, broadened my perspective on this therapeutic class, and reinforced my excitement to contribute to its continued advancement, particularly as CenExel remains at the forefront of this rapidly evolving area of research,” said Kaylie LoCascio, clinical research coordinator for CenExel Tampa.

This initiative reflects CenExel’s commitment to leading not only in scale, but in scientific and operational excellence, and maintaining scientific rigor on the forefront of every CenExel employee.

For more information, please visit cenexel.com or email contactus@cenexel.com.

###

Media Contact:

George Protopapadakis
Public Relations
CenExel
g.protopapadakis@cenexel.com

About CenExel

CenExel is a leading, wholly owned clinical research site network dedicated to supporting the life sciences industry in discovering and developing life-changing therapies.

CenExel provides unparalleled research support in the design and execution of complex clinical trials, leveraging scientific expertise, world-class Principal Investigators, advanced patient engagement strategies, premium data, and integrated operational excellence.

Located across multiple major metro areas, CenExel’s Centers of Excellence sites have conducted thousands of studies with precision, accuracy, and speed. The company’s unwavering commitment to quality, the patient experience, and client success ensures successful clinical development outcomes.

CenExel’s expertise and execution capabilities help pharmaceutical and biotech companies gain deeper insights into diseases, accelerating clinical development to deliver innovative treatments and improve global patient outcomes. To learn more visit www.cenexelresearch.com

SOURCE: CenExel Research

View the original press release on ACCESS Newswire